topic

160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy
Hitomi Hosoya, Mia Carleton, Kailee Tanaka, Brian Sworder, Vanna Hovanky, George Duran, Tian Zhang, Michael Khodadoust, David Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David Kurtz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A179; DOI: 10.1136/jitc-2023-SITC2023.0160
161 CUDU907 inhibits A549 proliferation by activating NDRG1
Yuxia Huang, Wentian Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A180; DOI: 10.1136/jitc-2023-SITC2023.0161
162 Extended antigen specific cellular responses by single-cell immune profiling
Kivin Jacobsen, Amalie Skak Scholler, Liselotte Brix

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A181; DOI: 10.1136/jitc-2023-SITC2023.0162
163 A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database
Prerna Jain, Michelle M Stein, Paul Fields, Bolesław Osinski, Luca Lonini, Ariane Lozac’hmeur, Rohan Joshi, Halla Nimeiri, Martin Stumpe, Kate Sasser, Catherine Igartua, Justin Guinney, Mary L Disis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A182-A184; DOI: 10.1136/jitc-2023-SITC2023.0163
164 The association between neurotrophic tropomycin receptor kinase (NTRK) variants of unknown significance (VUS’s) and response to immune checkpoint inhibitors in solid tumors
Moh’d Khushman, Andreas Seeber, Michael Iglesia, Kilannin Krysiak, Lulu Sun, Belal Firwana, Upender Manne

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A185; DOI: 10.1136/jitc-2023-SITC2023.0164
165 Microsampling for RNA biomarker profiling in blood
Lester Kobzik, Mikhail Makhanov, Alex Chenchik

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A186; DOI: 10.1136/jitc-2023-SITC2023.0165
166 High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with outcome on immune checkpoint inhibitors
Nithya Krishnamurthy, Daisuke Nishizaki, Scott M Lippman, Hirotaka Miyashita, Mary K Nesline, Sarabjot Pabla, Jeffrey M Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A187; DOI: 10.1136/jitc-2023-SITC2023.0166
167 Increased programmed cell death 1 ligand 2 (PD-L2) protein and transcript levels in triple negative breast cancer patients improve prognostic value through immune pathway activation
Dong Yeul Lee, Clara Ong, Bernett Lee, Stefano Perna, Joe Yeong, Puay Tan, Jabed Iqbal

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A188-A191; DOI: 10.1136/jitc-2023-SITC2023.0167
168 Associations of high toll-like receptor 3 gene expression and favorable anti-tumor immune microenvironment in metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitors
Mingjia Li, Komal Das, Giuseppe Giuliani, Anil Parwani, Daniel Spakowicz, Amir Mortazavi, Jayajit Das, Zihai Li, Yuanquan Yang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A192; DOI: 10.1136/jitc-2023-SITC2023.0168
169 immunoPETE: deciphering disease dynamics through comprehensive adaptive immune repertoire profiling
Hamid Mirebrahim, Hossein Asgharian, Florian Rubelt, Jan Berka, Dinesh Kumar

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A193; DOI: 10.1136/jitc-2023-SITC2023.0169

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages